Lattanzi, Simona http://orcid.org/0000-0001-8748-0083
Trinka, Eugen
Striano, Pasquale
Rocchi, Chiara
Salvemini, Sergio
Silvestrini, Mauro
Brigo, Francesco
Funding for this research was provided by:
Università Politecnica delle Marche
Article History
Accepted: 10 March 2021
First Online: 22 March 2021
Declarations
:
: No funding was received for the conduct of this study. Open access funding was provided by Università Politecnica delle Marche within the CRUI-CARE Agreement.
: Simona Lattanzi has received speaker’s or consultancy fees from Eisai, UCB Pharma, and GW Pharmaceuticals and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, and GW Pharmaceuticals. Eugen Trinka has received speaker’s honoraria from UCB Pharma, Biogen, Gerot-Lannach, Bial, Eisai, Takeda, Newbridge, Sunovion Pharmaceuticals Inc., LivaNova, and Novartis; consultancy funds from UCB Pharma, Biogen, Gerot-Lannach, Bial, Eisai, Takeda, Newbridge, GW Pharmaceuticals, Sunovion Pharmaceuticals Inc., and Novartis; and directorship funds from Neuroconsult GmbH. Eugen Trinka’s institution received grants from Biogen, Red Bull, Merck, UCB Pharma, European Union, FWF Österreichischer Fond zur Wissenschaftsförderung, and Bundesministerium für Wissenschaft und Forschung. Pasquale Striano received fees and research grants from GW Pharmaceuticals, Zogenyx, Biomarin, and Kolfarma s.r.l. Chiara Rocchi, Sergio Salvemini, and Mauro Silvestrini have no conflicts of interest that are directly relevant to the content of this study. Francesco Brigo acted as a consultant for Eisai.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: SL drafted the concept for the article, analyzed the data, and wrote the manuscript. SL, CR, and SS performed the literature search. ET, PS, MS, and FB critically revised the work. All authors contributed to the final manuscript.